News

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Weight-loss drug Wegovy (semaglutide) and its diabetes-focused cousin, Ozempic, have already upended the treatment of both obesity and diabetes, with sales of both drugs skyrocketing.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

Dr. Sanjaya Gupta, electrophysiologist at Saint Luke's Mid America Heart Institute, talks with KCTV about risk factors and new treatment available at Saint Luke's Atrial Fibrillation Clinic.

When Shannon Clarke, a 48-year-old, retired police officer, received a heart from Saint Luke’s Mid America Heart Institute, he had no idea just how transformational it would be. 

Trial device helps Seabrun “Candy” Hunter’s worn heart valve pump at a steady beat.